Saturday 17 October 2026
Export NRSN’s income statement to Excel — free account
NeuroSense Therapeutics Ltd.
NRSN Healthcare Biotechnology
Insiders bought in the last twelve months.
3.07
0.10
−3.15%
Follow NRSN
NeuroSense Therapeutics Ltd. (NRSN) P/E ratio
NeuroSense Therapeutics Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRAW Traws Pharma, Inc. compare | n/m |
| ENVB Enveric Biosciences, Inc. compare | n/m |
| EVGN Evogene Ltd. compare | n/m |
| TCRT Alaunos Therapeutics, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. | n/m |
| ORGS Orgenesis Inc. compare | n/m |
| IMNN Imunon, Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)